These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 14523037)

  • 1. A novel protective effect of erythropoietin in the infarcted heart.
    Parsa CJ; Matsumoto A; Kim J; Riel RU; Pascal LS; Walton GB; Thompson RB; Petrofski JA; Annex BH; Stamler JS; Koch WJ
    J Clin Invest; 2003 Oct; 112(7):999-1007. PubMed ID: 14523037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
    Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway.
    Tramontano AF; Muniyappa R; Black AD; Blendea MC; Cohen I; Deng L; Sowers JR; Cutaia MV; El-Sherif N
    Biochem Biophys Res Commun; 2003 Sep; 308(4):990-4. PubMed ID: 12927817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.
    Kim KH; Oudit GY; Backx PH
    J Pharmacol Exp Ther; 2008 Jan; 324(1):160-9. PubMed ID: 17928571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2.
    Kilic U; Kilic E; Soliz J; Bassetti CI; Gassmann M; Hermann DM
    FASEB J; 2005 Feb; 19(2):249-51. PubMed ID: 15556972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway].
    Zhang DG; Zhang FM; Zhang YQ; Zhou F; Gao X; Li CF; Cao KJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):912-6. PubMed ID: 17217721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I.
    Digicaylioglu M; Garden G; Timberlake S; Fletcher L; Lipton SA
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9855-60. PubMed ID: 15210945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways.
    Rafiee P; Shi Y; Su J; Pritchard KA; Tweddell JS; Baker JE
    Basic Res Cardiol; 2005 May; 100(3):187-97. PubMed ID: 15611843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model.
    Klopsch C; Furlani D; Gäbel R; Li W; Pittermann E; Ugurlucan M; Kundt G; Zingler C; Titze U; Wang W; Ong LL; Wagner K; Li RK; Ma N; Steinhoff G
    J Cell Mol Med; 2009 Apr; 13(4):664-79. PubMed ID: 19449462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8.
    Chong ZZ; Lin SH; Kang JQ; Maiese K
    J Neurosci Res; 2003 Mar; 71(5):659-69. PubMed ID: 12584724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?
    Chanséaume S; Azarnoush K; Maurel A; Bellamy V; Peyrard S; Bruneval P; Hagège AA; Menasché P
    Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):293-7. PubMed ID: 17669846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo.
    Bullard AJ; Govewalla P; Yellon DM
    Basic Res Cardiol; 2005 Sep; 100(5):397-403. PubMed ID: 15944807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of erythropoietin on myocardial infarction in rats: the role of AMP-activated protein kinase signaling pathway.
    Li XJ; Wang XW; Du YJ
    Am J Med Sci; 2011 Aug; 342(2):153-9. PubMed ID: 21415704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.
    Moon C; Krawczyk M; Paik D; Coleman T; Brines M; Juhaszova M; Sollott SJ; Lakatta EG; Talan MI
    J Pharmacol Exp Ther; 2006 Mar; 316(3):999-1005. PubMed ID: 16306273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase.
    Burger DE; Xiang FL; Hammoud L; Jones DL; Feng Q
    J Pharmacol Exp Ther; 2009 Jun; 329(3):900-7. PubMed ID: 19307451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
    Xu X; Cao Z; Cao B; Li J; Guo L; Que L; Ha T; Chen Q; Li C; Li Y
    Surgery; 2009 Sep; 146(3):506-14. PubMed ID: 19715808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes.
    Chen S; Liu J; Liu X; Fu Y; Zhang M; Lin Q; Zhu J; Mai L; Shan Z; Yu X; Yang M; Lin S
    J Ethnopharmacol; 2011 Sep; 137(1):263-70. PubMed ID: 21619920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol-3-kinase-Akt kinase and p42/p44 mitogen-activated protein kinases mediate neurotrophic and excitoprotective actions of a secreted form of amyloid precursor protein.
    Cheng G; Yu Z; Zhou D; Mattson MP
    Exp Neurol; 2002 Jun; 175(2):407-14. PubMed ID: 12061870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction.
    Kanashiro-Takeuchi RM; Takeuchi LM; Hatzistergos K; Quevedo H; Selem SM; Treuer AV; Premer C; Balkan W; Margitich I; Song Y; Hu Q; Hare JM
    Clin Transl Sci; 2011 Jun; 4(3):168-74. PubMed ID: 21707946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD.
    Shen J; Wu Y; Xu JY; Zhang J; Sinclair SH; Yanoff M; Xu G; Li W; Xu GT
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):35-46. PubMed ID: 19628748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.